CapsoVision, Inc.'s Quiet Period Set To Expire on August 11th (NASDAQ:CV)

Key Points

• CapsoVision's quiet period ends on August 11th, allowing underwriters to initiate research coverage following the IPO event.
• The company offered 5.5 million shares at $5.00 each during its initial public offering, totaling $27.5 million.
• Market analysts have issued varied ratings for CapsoVision, with Roth Capital setting a price target of $6.00 and a "buy" rating, while Benchmark initiated coverage with a target of $5.00 and a "speculative buy" rating.

CapsoVision's (NASDAQ:CV - Get Free Report) quiet period is set to end on Monday, August 11th. CapsoVision had issued 5,500,000 shares in its initial public offering on July 2nd. The total size of the offering was $27,500,000 based on an initial share price of $5.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analyst Weigh In

A number of research firms have commented on CV. Roth Capital set a $6.00 price target on shares of CapsoVision and gave the company a "buy" rating in a research report on Monday, July 28th. Benchmark initiated coverage on shares of CapsoVision in a research note on Monday, July 28th. They set a "speculative buy" rating and a $5.00 price target for the company. Finally, Wall Street Zen raised shares of CapsoVision to a "hold" rating in a research note on Sunday, July 13th.

CapsoVision Stock Performance

Shares of NASDAQ:CV traded up $0.08 on Thursday, reaching $4.30. 18,937 shares of the company's stock were exchanged, compared to its average volume of 377,553. CapsoVision has a twelve month low of $3.49 and a twelve month high of $5.72.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.